Celeris Therapeutics
Celeris Therapeutics is a Menlo Park-based drug discovery company founded in 2021 that combines deep learning with lab automation to develop targeted protein degradation therapeutics. It serves the pre-clinical biopharmaceutical pipeline as a research-stage platform with no disclosed commercial customers.
- Company typePrivate
- Founded2017
- HeadquartersMenlo Park, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Celeris Therapeutics does
Celeris Therapeutics is a Menlo Park, California-based drug discovery company founded in 2021 that applies deep learning combined with laboratory automation to develop therapeutics in the targeted protein degradation (TPD) modality. The company's platform is designed to accelerate the identification and optimization of degrader molecules — a therapeutic class that works by hijacking the cell's own protein disposal machinery to eliminate disease-causing proteins — by integrating computational prediction with automated wet-lab experimentation. This closed-loop approach is intended to compress design-make-test-analyze cycles relative to traditional medicinal chemistry workflows.
The company is privately held and small, with a reported headcount of 11-50 employees, and operates as a for-profit entity. Celeris has not disclosed a public-facing product catalog, named pipeline assets, or commercial partnerships in the available data; its current outputs are research-stage rather than revenue-generating. The company's go-to-market posture is consistent with a pre-clinical platform play, where long-term value creation depends on either internal pipeline advancement to IND-enabling stages, out-licensing of degrader programs, or strategic partnerships with larger pharmaceutical companies.
Between March 2021 and October 2022, Celeris raised approximately $17 million across five funding rounds from a mix of European and U.S. investors, led most recently by the European Innovation Council in two tranches. Earlier rounds brought in APEX Ventures, i&i Prague, Longevitytech.fund, Pace Ventures, and R42 Group. The investor mix — spanning biotech specialists, deep-tech funds, and longevity-focused capital — reflects the cross-disciplinary nature of the company's AI-biology platform. No disclosures of revenue, licensing income, or commercial customers were available in the input, consistent with a pre-revenue, research-stage operating model.
Celeris Therapeutics firmographics
Firmographics- Name
- Celeris Therapeutics
- Legal name
- Vavada
- Website
- https://celeristx.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Celeris Therapeutics is a Menlo Park-based drug discovery company founded in 2021 that combines deep learning with lab automation to develop targeted protein degradation therapeutics. It serves the pre-clinical biopharmaceutical pipeline as a research-stage platform with no disclosed commercial customers.
- Ownership category
- akta.pro rank
Celeris Therapeutics industry classification
Industry- Product category
- Biotechnology Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Celeris Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Markets served
Celeris Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Casino House Edge: Revenue generated from the mathematical house edge across slot machines, table games, and live dealer games. Average slot RTP stated at 95.5%, meaning the casino retains approximately 4.5% of wagers over time.
- VIP Program and Loyalty: Tiered VIP program with escalating perks including higher cashout limits, access to private tournaments, personal account managers, and exclusive bonus offers.
- Tournament Entry Fees: Formal tournaments where players compete for prize pools funded partly by entry mechanics; prizes range from $100 to $12,000.
- Bonus Wagering Requirements: Wagering requirements (x20-x35 multipliers) on bonus funds before withdrawal creates revenue from unfulfilled playthroughs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Pay-as-you-go | Welcome Bonus - 100 Free Spins on Great Pigsby Megaways |
| Freemium | Pay-as-you-go | First Deposit Match Bonus up to $1,000 |
| Usage-based | Monthly | Cashback - 10% Monthly |
| Subscription | Annual | VIP Tier Benefits |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels6 records
Celeris Therapeutics product offering
Product offeringCore offering
Celeris Therapeutics is a drug discovery company that uses deep learning combined with lab automation to accelerate the identification and optimization of targeted protein degradation therapeutics. Its work centers on designing degrader molecules (such as PROTACs) that can be developed into clinical assets for pharmaceutical partners or internal programs. The company operates as a discovery-stage biotech, leveraging AI-driven target identification and automated wet-lab workflows to compress traditional medicinal chemistry timelines.
Product overview
Vavada Online Casino is a single unified online gambling platform offering over 5000 games including slots, table games, live dealer games, crash games, and sports betting. The platform is accessible via desktop web browser, mobile browser, and dedicated iOS and Android applications. The ecosystem includes tournament systems, a VIP program with personalized account managers, and a bonus system with welcome bonuses, cashback, and promotional codes.
Differentiator
Problem solved
Functional benefit
Products and services
- Targeted Protein Degradation Discovery Platform Drug discovery service that combines AI-driven target prediction with automated wet-lab experimentation to identify and optimize targeted protein degrader candidates for pharmaceutical and biotechnology partners.
Quantifiable outcome
- Average 95.5% RTP across slots and table games, meaning 95% of bets return with multipliers from x1.1 to x100,000
- +3 more outcomes
Companies that use Celeris Therapeutics
Customer profileSegments4 records
Ideal customer profiles1 record
Celeris Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Celeris Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Curaçao Gaming Control BoardcoreRegulatory licensing authority providing international gaming license for legal operation. The regulator monitors random algorithm functioning, payout fund availability, and security against hacking to protect player rights.
- 41 Gaming Providers (NetEnt, Pragmatic Play, Play'n Go, Yggdrasil, PG Soft, Red Tiger, Quickspin, iSoftBet, Hacksaw Gaming, and others)coreContent partnership providing over 5,000 casino game titles across slots, table games, live dealer, and crash game categories. Providers include 1x2 Gaming, Amatic, Belatra Games, BGaming, Blueprint Gaming, EGT Digital, ELK, Endorphina, Habanero, Igrosoft, NetEnt, Nolimit City, Playson, Playtech, Push Gaming, Thunderkick, Yggdrasil, and others.
- Content Creator/Streamer PartnersminorAffiliate partners who stream casino gameplay on YouTube, provide reviews and tutorials, and distribute promotional codes to their audiences. Contact support for full partner list.
- 20 Financial Services (Payment Processors)corePayment processing partnerships enabling deposits and withdrawals across 20 currencies including cryptocurrency. Services ensure seamless financial operations without commissions.
Scale indicators8 records
Recent moves5 records
Expansion highlights4 records
Celeris Therapeutics competitors and assessment
Company assessmentDirect peers
- Arvinas: Pioneer and leader in clinical-stage PROTAC-based protein degradation. Most directly comparable to Celeris on the TPD modality, though at much later stage with partnered assets (Pfizer, Bayer) and FDA-submitted programs.
- Kymera Therapeutics: Clinical-stage TPD company with multiple degrader programs and major pharma partnerships (Sanofi, Vertex). Directly competes with Celeris for talent, targets, and pharma BD opportunities in protein degradation.
- C4 Therapeutics: Clinical-stage TPD company developing small-molecule degraders (e.g., CFT7455 for multiple myeloma). Direct peer in the protein degradation space with comparable scientific focus on targeted protein destruction.
- Foghorn Therapeutics: Discovery-stage TPD and chromatin-targeted company. Similar early-stage profile to Celeris and competing in the same protein-degradation talent and partnership ecosystem.
- Insilico Medicine: AI-native drug discovery company combining generative deep learning with automated wet-lab biology. Closest comparable on the AI/ML + lab automation thesis underlying Celeris's platform.
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput automated biology with ML. Comparable technology stack and modality-agnostic approach to Celeris's AI + lab automation model.
- Schrödinger: Computational drug discovery platform combining physics-based modeling with ML. Comparable in offering ML-driven discovery tools to pharma, though more mature, publicly traded, and software-licensing-heavy in business model.
- Generate Biomedicines: AI-driven generative biology platform designing protein therapeutics. Overlapping AI + lab automation thesis with Celeris, though focused on biologics generation rather than small-molecule TPD.
Broad incumbents
- Isomorphic Labs: Alphabet-owned AI drug discovery company with substantially more capital, compute, and AlphaFold-derived IP. A broader incumbent in AI-native drug discovery and a credible long-term competitor for pharma BD deals.
- Amgen: Large biopharma with internal TPD investment and partnerships (e.g., with Arvinas and Kymera). Represents both a structural competitive threat to TPD-discovery startups and a potential partner/acquirer for Celeris's platform.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Celeris Therapeutics social profiles
Digital presenceCeleris Therapeutics compliance and trust
Trust signalCompliance1 record
Celeris Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Celeris Therapeutics leadership team
Management profileNumber of profiles
Celeris Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Celeris Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Celeris Therapeutics
What does Celeris Therapeutics do?
Celeris Therapeutics is a drug discovery company that uses deep learning combined with lab automation to accelerate the identification and optimization of targeted protein degradation therapeutics. Its work centers on designing degrader molecules (such as PROTACs) that can be developed into clinical assets for pharmaceutical partners or internal programs. The company operates as a discovery-stage biotech, leveraging AI-driven target identification and automated wet-lab workflows to compress traditional medicinal chemistry timelines.
Is Celeris Therapeutics a public or private company?
Celeris Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Celeris Therapeutics founded?
Celeris Therapeutics was founded in 2017. It employs 11 to 50 people.
Where is Celeris Therapeutics based?
Celeris Therapeutics is headquartered in Menlo Park, United States, in the North America region.
How does Celeris Therapeutics make money?
Four revenue lines are on record. Casino House Edge is the primary driver. The others are VIP Program and Loyalty, tournament Entry Fees and bonus Wagering Requirements.
Who are Celeris Therapeutics's main competitors?
Direct peers on record are Arvinas, Kymera Therapeutics, C4 Therapeutics, Foghorn Therapeutics, Insilico Medicine, Recursion Pharmaceuticals, Schrödinger and Generate Biomedicines. Broad incumbents are Isomorphic Labs and Amgen.
Does Celeris Therapeutics have an API?
No public API is recorded for Celeris Therapeutics.
What industry is Celeris Therapeutics in?
Celeris Therapeutics's product category is Biotechnology Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714.